Research blog
Plain-language summaries of new HSV studies, trial results and regulatory decisions. Every post links to its original source.
Fred Hutch’s Keith Jerome on the road to a herpes cure
The scientist leading the best-known HSV gene-therapy program sat down to talk cure research. Here’s the background that makes the conversation worth your time.
Read the summary
Moderna posts results for its therapeutic HSV‑2 vaccine
Results from the Phase 1/2 study of mRNA‑1608 in adults with recurrent genital herpes are now public. Here’s what the trial was designed to answer.
Read the summary
Long-acting herpes pills finish Phase 1b
Assembly Bio completed follow-up for its two helicase-primase inhibitors. The headline number: 94% fewer days of viral shedding than placebo.
Read the summary
FDA fast-tracks review of pritelivir
If approved, it would be the first new HSV treatment in more than 20 years. A decision is due by the end of 2026.
Read the summary
Gilead licenses Assembly Bio’s herpes program
After positive early data, one of the world’s largest antiviral companies takes over development of two long-acting herpes drugs.
Read the summary
A simpler, safer gene therapy for herpes
Fred Hutch reported that a streamlined gene-editing treatment removed 90% or more of HSV‑1 in mice, with fewer side effects.
Read the summaryGet the next update in your inbox
One email per meaningful development. Unsubscribe any time.
Get research updates
Your name and email. That’s it.